ADTX Live signals | Maximize Profits with Getagraph.com

SELL 134124 min ago

@ $4.00

Issued: 13 Feb 2024 @ 14:29

Return: -49.75%

Live Chart Being Loaded With Signals

Commentary (16 May 2024 @ 16:00):

Stats
Today's Volume	48 598.00
Average Volume	365 959
Market Cap	3.94M
EPS	$0 ( 2024-04-02 )
Next earnings date	( $-3.33 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0.0320 (1.59%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-08	Runge Jeffrey W.	Buy	470	Options (right to buy)
2023-11-08	Albanna Rowena	Buy	4 702	Options (right to buy)
2023-11-08	Nelson Charles Athle	Buy	470	Options (right to buy)
2023-11-08	Albanna Amro A.	Buy	9 404	Options (right to buy)
2023-11-08	Pankovcin Corinne	Buy	4 702	Options (right to buy)

INSIDER POWER
26.70
Last 84 transactions
Buy: 1 934 500 \| Sell: 1 185 103

Volume Correlation

Long: -0.24 (neutral)

Short: 0.16 (neutral)

Signal:(47.799) Neutral

ADiTx Therapeutics, Inc. Correlation

10 Most Positive Correlations
OGI	0.974
VERB	0.971
MRIN	0.964
WATT	0.963
MMAT	0.962
DISH	0.961
ARVL	0.961
HFWA	0.96
OPINL	0.959
BANR	0.958

10 Most Negative Correlations
MSDA	-0.971
TIOA	-0.961
BRIVU	-0.953
WINV	-0.951
KYCH	-0.947
GFGD	-0.946
GLLI	-0.945
FICV	-0.944
HWEL	-0.935
MITA	-0.935

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ADiTx Therapeutics, Inc. Correlation - Currency/Commodity

-0.66
( moderate negative )

-0.61
( weak negative )

0.00
( neutral )

-0.41
( neutral )

-0.64
( weak negative )

0.41
( neutral )

ADiTx Therapeutics, Inc. Financials

Annual	2023
Revenue:	$645 176
Gross Profit:	$-654 243 (-101.41 %)
EPS:	$-107.10

FY	2023
Revenue:	$645 176
Gross Profit:	$-654 243 (-101.41 %)
EPS:	$-107.10

FY	2022
Revenue:	$933 715
Gross Profit:	$166 936 (17.88 %)
EPS:	$-608.04

FY	2021
Revenue:	$105 034
Gross Profit:	$27 055.00 (25.76 %)
EPS:	$-6.72

Financial Reports:

No articles found.

ADiTx Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ADiTx Therapeutics, Inc.

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Realtime updates for ADiTx Therapeutics, Inc. [ADTX]

Upcoming Earnings Alert

ADiTx Therapeutics, Inc. Options Data

Calls

Puts